Clinical Applications of Radiomics in Non-small Cell Lung Cancer Patients with Immune Checkpoint Inhibitor-related Pneumonitis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Oct 6

PMID 37799725

Authors

Yang Shu

Wei Xu

Rui Su

Pancen Ran

Lei Liu

Zhizhao Zhang

Jing Zhao

Zhen Chao

Guobin Fu

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) modulate the body's immune function to treat tumors but may also induce pneumonitis. Immune checkpoint inhibitor-related pneumonitis (ICIP) is a serious immune-related adverse event (irAE). Immunotherapy is currently approved as a first-line treatment for non-small cell lung cancer (NSCLC), and the incidence of ICIP in NSCLC patients can be as high as 5%-19% in clinical practice. ICIP can be severe enough to lead to the death of NSCLC patients, but there is a lack of a gold standard for the diagnosis of ICIP. Radiomics is a method that uses computational techniques to analyze medical images (e.g., CT, MRI, PET) and extract important features from them, which can be used to solve classification and regression problems in the clinic. Radiomics has been applied to predict and identify ICIP in NSCLC patients in the hope of transforming clinical qualitative problems into quantitative ones, thus improving the diagnosis and treatment of ICIP. In this review, we summarize the pathogenesis of ICIP and the process of radiomics feature extraction, review the clinical application of radiomics in ICIP of NSCLC patients, and discuss its future application prospects.

Citing Articles

Automatic machine learning accurately predicts the efficacy of immunotherapy for patients with inoperable advanced non-small cell lung cancer using a computed tomography-based radiomics model.

Lin S, Ma Z, Yao Y, Huang H, Chen W, Tang D Diagn Interv Radiol. 2025; 31(2):130-140.

PMID: 39817633 PMC: 11880869. DOI: 10.4274/dir.2024.242972.

A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence.

Liu X, Chen H, Tan G, Zhong L, Jiang H, Smith S Front Immunol. 2024; 15():1496627.

PMID: 39669560 PMC: 11634813. DOI: 10.3389/fimmu.2024.1496627.

References

Chen J, Dhahbi J . Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods. Sci Rep. 2021; 11(1):13323. PMC: 8233431. DOI: 10.1038/s41598-021-92725-8. View

Zhou Y, Ma Y, Shi H, Du Y, Huang Y . Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China. Sci Rep. 2018; 8(1):15426. PMC: 6194063. DOI: 10.1038/s41598-018-33816-x. View

Kawahara D, Imano N, Nishioka R, Ogawa K, Kimura T, Nakashima T . Prediction of radiation pneumonitis after definitive radiotherapy for locally advanced non-small cell lung cancer using multi-region radiomics analysis. Sci Rep. 2021; 11(1):16232. PMC: 8355298. DOI: 10.1038/s41598-021-95643-x. View

Hawkins D . The problem of overfitting. J Chem Inf Comput Sci. 2004; 44(1):1-12. DOI: 10.1021/ci0342472. View

Luo W, Wang Z, Tian P, Li W . Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2018; 144(10):1851-1859. DOI: 10.1007/s00432-018-2707-4. View

Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z . Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology. 2016; 281(3):947-957. DOI: 10.1148/radiol.2016152234. View

Nishino M, Hatabu H, Hodi F, Ramaiya N . Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precis Oncol. 2020; 1. PMC: 7446404. DOI: 10.1200/PO.17.00026. View

Cousin F, Louis T, Dheur S, Aboubakar F, Ghaye B, Occhipinti M . Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2023; 15(7). PMC: 10093736. DOI: 10.3390/cancers15071968. View

Yushkevich P, Gao Y, Gerig G . ITK-SNAP: An interactive tool for semi-automatic segmentation of multi-modality biomedical images. Annu Int Conf IEEE Eng Med Biol Soc. 2017; 2016:3342-3345. PMC: 5493443. DOI: 10.1109/EMBC.2016.7591443. View

10.

Atchley W, Alvarez C, Saxena-Beem S, Schwartz T, Ishizawar R, Patel K . Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. Chest. 2021; 160(2):731-742. PMC: 8411447. DOI: 10.1016/j.chest.2021.02.032. View

11.

Yoneda K, Scranton J, Cadogan M, Tassell V, Nadanaciva S, Wilner K . Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials. Clin Lung Cancer. 2017; 18(5):472-479. DOI: 10.1016/j.cllc.2017.03.004. View

12.

Xie Y, Zhao H, Guo Y, Meng F, Liu X, Zhang Y . A PET/CT nomogram incorporating SUVmax and CT radiomics for preoperative nodal staging in non-small cell lung cancer. Eur Radiol. 2021; 31(8):6030-6038. PMC: 8270849. DOI: 10.1007/s00330-020-07624-9. View

13.

Suresh K, Naidoo J, Lin C, Danoff S . Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest. 2018; 154(6):1416-1423. PMC: 6335259. DOI: 10.1016/j.chest.2018.08.1048. View

14.

Arroyo-Hernandez M, Maldonado F, Lozano-Ruiz F, Munoz-Montano W, Nunez-Baez M, Arrieta O . Radiation-induced lung injury: current evidence. BMC Pulm Med. 2021; 21(1):9. PMC: 7788688. DOI: 10.1186/s12890-020-01376-4. View

15.

Zhang Y, Oikonomou A, Wong A, Haider M, Khalvati F . Radiomics-based Prognosis Analysis for Non-Small Cell Lung Cancer. Sci Rep. 2017; 7:46349. PMC: 5394465. DOI: 10.1038/srep46349. View

16.

Cousin F, Desir C, Ben Mustapha S, Mievis C, Coucke P, Hustinx R . Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer. Radiother Oncol. 2021; 157:47-55. DOI: 10.1016/j.radonc.2021.01.001. View

17.

Munegowda M, Deng Y, Mulligan S, Xiang J . Th17 and Th17-stimulated CD8⁺ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother. 2011; 60(10):1473-84. PMC: 11028972. DOI: 10.1007/s00262-011-1054-y. View

18.

Qin K, Fu X . [Research Progress in Imaging-based Diagnosis of Benign and Malignant  Enlarged Lymph Nodes in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2023; 26(1):31-37. PMC: 9987091. DOI: 10.3779/j.issn.1009-3419.2023.101.01. View

19.

Yoshino K, Nakayama T, Ito A, Sato E, Kitano S . Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. BMC Cancer. 2019; 19(1):1019. PMC: 6819390. DOI: 10.1186/s12885-019-6138-7. View

20.

Kocak B, Durmaz E, Ates E, Kilickesmez O . Radiomics with artificial intelligence: a practical guide for beginners. Diagn Interv Radiol. 2019; 25(6):485-495. PMC: 6837295. DOI: 10.5152/dir.2019.19321. View